ARTICLE | Clinical News

CHMP backs approval for Pfizer's AML triple combo

March 2, 2018 12:31 AM UTC

EMA's CHMP recommended approval of Mylotarg gemtuzumab ozogamicin from Pfizer Inc. (NYSE:PFE) in combination with daunorubicin and cytarabine to treat previously untreated, CD33-positive acute myelogenous leukemia (AML), except acute promyelocytic leukemia (APL), in patients ages 15 and older...

BCIQ Company Profiles

Pfizer Inc.

BCIQ Target Profiles